Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study
暂无分享,去创建一个
T. Peters | C. Cooper | J. Kanis | D. Torgerson | E. McCloskey | S. Clarke | L. Shepstone | R. Fordham | R. Holland | H. Johansson | N. Harvey | T. O’Neill | I. Harvey | T. Marshall | N. Gittoes | A. Howe | N. Redmond | E. Lenaghan | A. Heawood | C. Cooper
[1] C. Cooper,et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.
[2] J. Kanis,et al. The Effect of Abaloparatide‐SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] C. Cooper,et al. UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.
[4] C. Cooper,et al. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting , 2017, Osteoporosis International.
[5] C. Cooper,et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures , 2017, Osteoporosis International.
[6] C. Cooper,et al. A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.
[7] J. Kanis,et al. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.
[8] J. Kanis,et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.
[9] E. McCloskey,et al. A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base , 2015, Osteoporosis International.
[10] J. Kanis,et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] T. Peters,et al. Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. , 2012, Family practice.
[12] T. Peters,et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study , 2012, Osteoporosis International.
[13] J. Kanis,et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® , 2011, Osteoporosis International.
[14] J. Kanis,et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.
[15] J. Kanis,et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.
[16] J. Kanis,et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.
[17] O. Johnell,et al. FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.
[18] O Johnell,et al. A family history of fracture and fracture risk: a meta-analysis. , 2004, Bone.